HOME >> BIOLOGY >> NEWS
The future of HIV therapeutics is brightening, according to Gladstone Institutes Director

Recent discoveries about the way that HIV infects cells are propelling the development of a broad spectrum of promising new antiviral drugs, according to an invited commentary on the topic in the current issue of Nature Immunology (August 27, 2004).

The assessment is made by Gladstone Institute of Virology and Immunology (GIVI) Director Warner Greene, MD, PhD, who also serves as professor of medicine, microbiology and immunology at the University of California, San Francisco.

In the piece, Greene points out that basic research on HIV, a relatively simple pathogen with only nine genes encoding 15 proteins, are leading to compelling new therapies that deny the initial entry of HIV into its cellular host. In addition, fast-moving research of naturally occurring factors with potent antiviral properties is opening the way for future development of an entirely new class of anti-HIV drugs.

New agents that block the first step in HIV's life cycle, the entry of the HIV virion (a single virus particle) into host CD4 T-cells, are quickly moving down the drug development pipeline. Chief among these therapeutics are drugs known as chemokine receptor antagonists that interfere with HIV's ability to bind to CCR5, one of two key surface receptors needed for the virus to penetrate the cell. Although these HIV co-receptors were identified only seven years ago, basic studies performed by both GIVI investigators and scientists around the world have helped accelerate clinical development of CCR5 antagonists as a new class of anti-HIV drugs. Several major pharmaceutical companies are now racing to the finishing line.

These advances address but one of the three steps required for successful entry of the HIV virus. The other two steps involve the attachment of HIV virions to surface CD4 receptors and the final fusion of virions to target cells. These steps are also being targeted with new antiviral drugs. Combinations of inhibitors acting at each o
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-695-3833
University of California - San Francisco
27-Aug-2004


Page: 1 2 3

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Charting the future in prostate cancer care: A call to action
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. Engineering endurance: The future of the Olympics?
6. The future of nanotechnology
7. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
8. Endometriosis: Could angiostatic therapy be the new treatment of the future?
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. Plant pathologists to discuss the future of organic farming
11. Stem cells commit to a future of fat with one signal

Post Your Comments:
(Date:7/21/2014)... have meaning? If you say "dog" to a friend, ... University philosopher Elliott Wagner aims to address these types ... long-standing philosophical questions about semantic meaning. Wagner, assistant professor ... are collaborating to use game theory to analyze communication ... a cappuccino at a coffee shop, I usually don,t ...
(Date:7/21/2014)... to climate change, due to greenhouse gasses emitted by ... the rise and that beef cattle are responsible for ... animals. It is published by Climactic Change . ... it comes to climate change. It is released by ... portion of greenhouse gas totals. But methane and nitrous ...
(Date:7/21/2014)... the strength of immune response, rather than with the ... the virus, might be a better way to reduce ... Washington, Seattle. She and her collaborators have now taken ... H7N9 influenza, and their work has already led to ... strain. The research is published ahead of print in ...
Breaking Biology News(10 mins):Philosopher uses game theory to understand how words, actions acquire meaning 2Climate: Meat turns up the heat 2Potential new flu drugs target immune response, not virus 2
(Date:7/18/2014)... N.Y. , July 18, 2014 Regeneron ... its second quarter 2014 financial and operating results on ... open.  The Company will host a conference call and ... Conference Call InformationTo access this call, ... link to the webcast may be accessed from the ...
(Date:7/18/2014)... is, most of the atoms in our environment are ... outer parts of atoms equals the number of protons ... more electrons are plucked away from the atoms, the ... the nucleus. This enhanced pull, causing the atoms ... less vulnerable to the distractions of their environment, making ...
(Date:7/18/2014)... (PRWEB) July 18, 2014 Global ... with US offices in Cambridge, MA, announces the ... Assay and Software product that leverages the power ... the Illumina® MiSeq sequencing platform. The assay and ... Children’s Hospital of Philadelphia (CHOP) and will include ...
(Date:7/18/2014)... 18, 2014 The International Wheat Genome Sequencing ... a draft sequence of the bread wheat genome. The ... and evolution of the large, complex genome of the ... genetic blueprint is an invaluable resource to plant science ... at their disposal a set of tools enabling them ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3Genetic Blueprint of Bread Wheat Genome Unveiled 2Genetic Blueprint of Bread Wheat Genome Unveiled 3
Cached News: